skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge

Abstract

Here, the safety and efficacy of an experimental, replication-deficient, human adenovirus-vectored foot-and-mouth disease virus (FMDV) serotype A24 Cruzeiro capsid-based subunit vaccine (AdtA24) was examined in eight independent cattle studies. AdtA24 non-adjuvanted vaccine was administered intramuscularly to a total of 150 steers in doses ranging from approximately 1.0 × 108 to 2.1 × 1011 particle units per animal. No detectable local or systemic reactions were observed after vaccination. At 7 days post-vaccination (dpv), vaccinated and control animals were challenged with FMDV serotype A24 Cruzeiro via the intradermal lingual route. Vaccine efficacy was measured by FMDV A24 serum neutralizing titers and by protection from clinical disease and viremia after challenge. The results of eight studies demonstrated a strong correlation between AdtA24 vaccine dose and protection from clinical disease (R2 = 0.97) and viremia (R2 = 0.98). There was also a strong correlation between FMDV A24 neutralization titers on day of challenge and protection from clinical disease (R2 = 0.99). Vaccination with AdtA24 enabled differentiation of infected from vaccinated animals (DIVA) as demonstrated by the absence of antibodies to the FMDV nonstructural proteins in vaccinates prior to challenge. Lack of AdtA24 vaccine shedding after vaccination was indicated by the absence of neutralizing antibodymore » titers to both the adenovector and FMDV A24 Cruzeiro in control animals after co-mingling with vaccinated cattle for three to four weeks. In summary, a non-adjuvanted AdtA24 experimental vaccine was shown to be safe, immunogenic, consistently protected cattle at 7 dpv against direct, homologous FMDV challenge, and enabled differentiation of infected from vaccinated cattle prior to challenge.« less

Authors:
; ; ; ; ; ; ; ; ; ; ; ;
Publication Date:
Research Org.:
Oak Ridge Inst. for Science and Education (ORISE), Oak Ridge, TN (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1390387
Alternate Identifier(s):
OSTI ID: 1494695
Grant/Contract Number:  
AC05-06OR23100; HSHQDC-07-9-00004; GS-23F-8006H; HSHQDC-8-C-00011; HSHQPD-07-X-00003
Resource Type:
Published Article
Journal Name:
Vaccine
Additional Journal Information:
Journal Name: Vaccine Journal Volume: 34 Journal Issue: 27; Journal ID: ISSN 0264-410X
Publisher:
Elsevier
Country of Publication:
United Kingdom
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES; Foot-and-mouth disease virus; FMDV serotype A24 Cruzeiro; Replication-deficient human adenovirus vectored vaccine; DIVA; Vaccine efficacy

Citation Formats

Schutta, Christopher, Barrera, José, Pisano, Melia, Zsak, Laszlo, Grubman, Marvin J., Mayr, Gregory A., Moraes, Mauro P., Kamicker, Barbara J., Brake, David A., Ettyreddy, Damodar, Brough, Douglas E., Butman, Bryan T., and Neilan, John G. Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge. United Kingdom: N. p., 2016. Web. doi:10.1016/j.vaccine.2015.12.018.
Schutta, Christopher, Barrera, José, Pisano, Melia, Zsak, Laszlo, Grubman, Marvin J., Mayr, Gregory A., Moraes, Mauro P., Kamicker, Barbara J., Brake, David A., Ettyreddy, Damodar, Brough, Douglas E., Butman, Bryan T., & Neilan, John G. Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge. United Kingdom. doi:10.1016/j.vaccine.2015.12.018.
Schutta, Christopher, Barrera, José, Pisano, Melia, Zsak, Laszlo, Grubman, Marvin J., Mayr, Gregory A., Moraes, Mauro P., Kamicker, Barbara J., Brake, David A., Ettyreddy, Damodar, Brough, Douglas E., Butman, Bryan T., and Neilan, John G. Wed . "Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge". United Kingdom. doi:10.1016/j.vaccine.2015.12.018.
@article{osti_1390387,
title = {Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge},
author = {Schutta, Christopher and Barrera, José and Pisano, Melia and Zsak, Laszlo and Grubman, Marvin J. and Mayr, Gregory A. and Moraes, Mauro P. and Kamicker, Barbara J. and Brake, David A. and Ettyreddy, Damodar and Brough, Douglas E. and Butman, Bryan T. and Neilan, John G.},
abstractNote = {Here, the safety and efficacy of an experimental, replication-deficient, human adenovirus-vectored foot-and-mouth disease virus (FMDV) serotype A24 Cruzeiro capsid-based subunit vaccine (AdtA24) was examined in eight independent cattle studies. AdtA24 non-adjuvanted vaccine was administered intramuscularly to a total of 150 steers in doses ranging from approximately 1.0 × 108 to 2.1 × 1011 particle units per animal. No detectable local or systemic reactions were observed after vaccination. At 7 days post-vaccination (dpv), vaccinated and control animals were challenged with FMDV serotype A24 Cruzeiro via the intradermal lingual route. Vaccine efficacy was measured by FMDV A24 serum neutralizing titers and by protection from clinical disease and viremia after challenge. The results of eight studies demonstrated a strong correlation between AdtA24 vaccine dose and protection from clinical disease (R2 = 0.97) and viremia (R2 = 0.98). There was also a strong correlation between FMDV A24 neutralization titers on day of challenge and protection from clinical disease (R2 = 0.99). Vaccination with AdtA24 enabled differentiation of infected from vaccinated animals (DIVA) as demonstrated by the absence of antibodies to the FMDV nonstructural proteins in vaccinates prior to challenge. Lack of AdtA24 vaccine shedding after vaccination was indicated by the absence of neutralizing antibody titers to both the adenovector and FMDV A24 Cruzeiro in control animals after co-mingling with vaccinated cattle for three to four weeks. In summary, a non-adjuvanted AdtA24 experimental vaccine was shown to be safe, immunogenic, consistently protected cattle at 7 dpv against direct, homologous FMDV challenge, and enabled differentiation of infected from vaccinated cattle prior to challenge.},
doi = {10.1016/j.vaccine.2015.12.018},
journal = {Vaccine},
number = 27,
volume = 34,
place = {United Kingdom},
year = {2016},
month = {6}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
DOI: 10.1016/j.vaccine.2015.12.018

Citation Metrics:
Cited by: 12 works
Citation information provided by
Web of Science

Figures / Tables:

Table 1 Table 1: Summary of eight independent AdtA24 vaccine efficacy studies in which steers were challenged at 7 days post-vaccination with FMDV serotype A24 Cruzeiro.

Save / Share:
Figures/Tables have been extracted from DOE-funded journal article accepted manuscripts.